Accepted into Campath Trial at NIH
Hey Y'all!
I got word Tuesday that I have been accepted into the National Institutes of Health's Campath trial for younger (I feel less bald and less grey every time I get to use that adjective!), low-risk MDSers.
I am pretty stoked about this, because I am convinced (after much careful study) that the kind of MDS I have should respond to immunosuppression. And I like the idea that Campath is more of a rifle shot at a couple types of T-cells instead of a shotgun applied to the whole immune system.
We'll be looking for transfusion independence and normal cytogenetics.
Now I just have to figure out how to fit the two weeks at NIH into running a small business. Looking at the calendar, I may finish up with the Campath on Christmas Eve. Yikes!
Greg
__________________
Greg, 59, dx MDS RCMD Int-1 03/10, 8+ & Dup1(q21q31). NIH Campath 11/2010. Non-responder. Tiny telomeres. TERT mutation. Danazol at NIH 12/11. TX independent 7/12. Pancreatitis 4/15. 15% blasts 4/16. DX RAEB-2. Beginning Vidaza to prep for MUD STC. Check out my blog at www.greghankins.com
|